Anteris Technologies Global (NASDAQ:AVR) Earns “Overweight” Rating from Cantor Fitzgerald

Anteris Technologies Global (NASDAQ:AVR)‘s stock had its “overweight” rating reiterated by equities researchers at Cantor Fitzgerald in a research report issued on Wednesday, Benzinga reports. They presently have a $15.00 target price on the stock. Cantor Fitzgerald’s price objective indicates a potential upside of 137.19% from the company’s current price.

AVR has been the topic of a number of other reports. Weiss Ratings restated a “sell (d-)” rating on shares of Anteris Technologies Global in a report on Wednesday, August 26th. Barclays upgraded shares of Anteris Technologies Global to a “hold” rating in a report on Wednesday, October 7th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $14.00.

Anteris Technologies Global Trading Down 2.0%

Shares of AVR stock traded down $0.13 during trading on Wednesday, reaching $6.32. 113,252 shares of the company’s stock traded hands, compared to its average volume of 1,115,739. The firm’s 50-day moving average is $8.32 and its 200 day moving average is $8.05. The company has a market capitalization of $616.34 million, a P/E ratio of -3.25 and a beta of 1.87. Anteris Technologies Global has a 1 year low of $3.30 and a 1 year high of $11.06.

Anteris Technologies Global (NASDAQ:AVR) last posted its earnings results on Tuesday, August 11th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.09). Anteris Technologies Global had a negative return on equity of 77.69% and a negative net margin of 4,619.27%. The company had revenue of $1.01 million during the quarter, compared to analysts’ expectations of $1.50 million. During the same period in the prior year, the business posted ($0.58) earnings per share. As a group, sell-side analysts predict that Anteris Technologies Global will post -1.21 earnings per share for the current fiscal year.

Insider Transactions at Anteris Technologies Global

In other Anteris Technologies Global news, major shareholder L1 Capital Pty Ltd purchased 272,695 shares of Anteris Technologies Global stock in a transaction dated Tuesday, October 6th. The shares were acquired at an average price of $7.18 per share, with a total value of $1,957,950.10. Following the completion of the transaction, the insider owned 6,358,271 shares of the company’s stock, valued at $45,652,385.78. This trade represents a 4.48% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last 90 days, insiders purchased 1,554,730 shares of company stock valued at $11,694,513 and sold 3,008,459 shares valued at $25,243,576. 4.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Anteris Technologies Global

Hedge funds have recently modified their holdings of the business. Cetera Investment Advisers boosted its holdings in Anteris Technologies Global by 64.7% in the 1st quarter. Cetera Investment Advisers now owns 16,550 shares of the company’s stock worth $92,000 after acquiring an additional 6,500 shares during the period. Bank of America Corp DE increased its holdings in Anteris Technologies Global by 12.6% in the first quarter. Bank of America Corp DE now owns 68,755 shares of the company’s stock valued at $382,000 after purchasing an additional 7,688 shares during the last quarter. Legal & General Group Plc bought a new stake in Anteris Technologies Global during the 2nd quarter worth $78,000. Bartlett & CO. Wealth Management LLC increased its position in Anteris Technologies Global by 174.5% in the first quarter. Bartlett & CO. Wealth Management LLC now owns 12,900 shares of the company’s stock worth $79,000 after buying an additional 8,200 shares during the last quarter. Finally, Abel Hall LLC bought a new position in Anteris Technologies Global during the 1st quarter valued at approximately $63,000.

About Anteris Technologies Global

Anteris Technologies Global is a clinical-stage structural heart company developing technologies intended to treat aortic valve disease. The company’s lead product is the DurAVR transcatheter heart valve, which is designed to replicate the performance characteristics of a healthy human aortic valve and restore more natural blood flow.

Anteris uses its proprietary ADAPT tissue-engineering technology to create heart-valve materials designed for durability and biocompatibility. The company is focused primarily on transcatheter aortic valve replacement and related structural-heart applications, with its products progressing through clinical development and regulatory evaluation rather than broad commercial distribution.

The company has Australian origins and maintains operations and clinical-development activities in both Australia and the United States.